Iran vs Madagascar: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Iran
54.0%
in 2025
Madagascar
56.0%
in 2025
Iran rank
153rd
Madagascar rank
151st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Iran
- Madagascar
How they compare
Madagascar currently reports 56.0% against 54.0% in Iran, a difference of 2.0%.
Across all 18 years both countries report, Madagascar has been ahead every year.
Iran ranks 153rd and Madagascar ranks 151st of 194 countries.
Madagascar has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Iran | Madagascar | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | β |
| 2010s | 0.0% | 47.6% | 47.6% | Madagascar |
| 2020s | 9.0% | 60.7% | 51.7% | Madagascar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Iran or Madagascar?
- Madagascar, at 56.0% against 54.0% in Iran as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Iran and Madagascar?
- 2.0%, with Madagascar ahead.
- How many years of comparable data are there for Iran and Madagascar?
- 18 years are reported by both, from 2008 to 2025.
- How do Iran and Madagascar rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Iran ranks 153rd and Madagascar ranks 151st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.